Key Takeaways

  • A Financial Times report of Merger talks between AstraZeneca and Bristol Myers Squibb sent shares down 8.96% on 3 August 2026, wiping over £17bn off Market Value .
  • Reuters subsequently reported a senior source saying there were no discussions between the companies, and shares recovered around 3%.
  • H1 2026 total Revenue rose 6% at constant exchange rates to $30.7 billion, with core EPS up 11% CER to $5.21.
  • Oncology generated $14.1 billion of H1 revenue, up 15% and now 46% of the group total, while BioPharmaceuticals revenue fell 5%.
  • Management reaffirmed its ambition to reach $80 billion in annual revenue by 2030, alongside a $50 billion pledge to expand US Manufacturing .

AstraZeneca (LSE:AZN) has spent the past fortnight at the centre of the pharmaceutical industry's biggest rumour in years. Reports that Britain's most valuable listed company was discussing a near-$400 billion combination with US rival Bristol Myers Squibb sent its shares into their steepest one-day fall in over a year, only for the story to unravel within days. Behind the noise, the underlying Business kept moving: the group posted double-digit core Earnings growth for H1 2026 and reaffirmed its ambition to reach $80 billion in annual revenue by 2030.

What Happened

On Sunday 2 August, the Financial Times reported that AstraZeneca (LSE:AZN) had held talks about a merger with Bristol Myers Squibb, a deal that would have created a combined group worth close to $400 billion. The following Monday, AstraZeneca shares fell 8.96%, closing at 11,500p and wiping more than £17 billion off its Market Capitalisation — the steepest single-day drop since April 2025, according to Investing Cube. Bristol Myers shares were little moved.

Investors reacted with scepticism. Reuters Breakingviews questioned the logic of AstraZeneca, long run as an organic-growth story, buying US scale just as its own pipeline delivers, while others flagged antitrust risk given both firms' heavy oncology exposure. By Wednesday 5 August, Reuters reported a senior source saying "there is no deal between AstraZeneca and BMS... there never was a deal to be done, and there are no discussions between the companies." Neither company confirmed or denied the reports directly, but AstraZeneca shares recovered around 3% on the Reuters report.

Why It Matters

The episode matters less for what it says about a merger that, on the available reporting, never materialised, and more for what it revealed about sentiment. A near-9% swing on unconfirmed reports shows how sensitive AstraZeneca's rating has become to any hint of deviation from its growth strategy, and how quickly shareholders mark down a deal combining a huge premium, integration risk and antitrust uncertainty. It also lands as US pharma M&A and geopolitics — tariffs, drug-pricing pressure and a White House push for domestic manufacturing — reshape capital allocation across the sector.

Latest Financial and Operational Performance

The merger noise broke shortly after AstraZeneca published its half-year results. For H1 2026, the group reported total revenue of $30.7 billion, up 6% at constant exchange rates (CER), and core EPS of $5.21, up 11% CER; reported EPS was $3.60, up 4%. In Q2 alone, revenue reached $15.384 billion, up 5% CER, while core EPS of $2.63 beat consensus of around $2.48, driven largely by oncology.

Oncology remains the growth engine, generating $14.1 billion of H1 revenue, up 15% and now 46% of the group total. Rare disease revenue rose 11% to $4.9 billion, while BioPharmaceuticals — cardiovascular, renal and respiratory medicines — fell 5% to $11.2 billion. Management reconfirmed full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, both at CER.

Key Numbers

  • H1 2026 total revenue: $30.7bn, up 6% at constant exchange rates
  • H1 2026 core EPS: $5.21, up 11% CER; reported EPS $3.60, up 4%
  • Q2 2026 revenue: $15.384bn; core EPS $2.63 versus consensus of around $2.48
  • Oncology H1 2026 revenue: $14.1bn (46% of group total), up 15%
  • Shares fell 8.96% on 3 August 2026, wiping over £17bn off market value
  • Current market capitalisation: around £184.5bn, shares near 11,900p
  • Pipeline: 183 total projects; 116 new molecular entities in Phase II/III; 30 approvals across major markets since Q4 2025

Growth Opportunities

AstraZeneca's own strategy, rather than any Acquisition , remains the primary route to its $80 billion revenue ambition, up from $55.6 billion in 2025. The late-stage pipeline is unusually deep, with 21 late-stage new molecular entities and four Assets already under regulatory review, spanning oncology, cardiometabolic disease, immunology and rare disease. Oncology remains management's single largest growth driver, having grown to 46% of group revenue.

The company has also pledged $50 billion to expand US research, manufacturing and patient access to new medicines, including a new plant near Charlottesville, Virginia, set to create thousands of jobs — part of a broader wave of drugmakers deepening their US footprint amid Tariff threats and pressure for domestic production. That hedges AstraZeneca against US trade-policy risk while supporting its ambitions without the execution risk of a transformational acquisition.

Risks Investors Should Know

The clearest near-term risk is Patent expiry, most notably on diabetes drug Farxiga, one of AstraZeneca's larger BioPharmaceuticals products, where loss-of-exclusivity pressure is expected to weigh on that division. BioPharmaceuticals' 5% H1 revenue decline already shows not every part of the portfolio is growing, leaving oncology to carry a disproportionate share of momentum.

The Bristol Myers episode is a reminder of event risk: even unconfirmed deal speculation triggered a near-9% share price swing, and investors cannot fully discount management exploring further large-scale M&A given the debate over whether AstraZeneca needs more US scale. Beyond that, the company faces sector-wide risks from US drug-pricing reform, tariff exposure on imports, and the ordinary hazards of late-stage trial failure across a pipeline of well over 100 programmes.

What to Watch Next

Investors should watch for any formal statement clarifying the status of talks, given UK Takeover Code disclosure obligations that sustained speculation can trigger. Further catalysts include Phase III readouts and approvals building on the 30 already achieved since Q4 2025. Progress on the Virginia site and wider US Investment programme will signal execution of the organic strategy, while third-quarter results, due later in 2026, should show whether the Farxiga patent cliff and BioPharmaceuticals softness are stabilising or deepening.

Outlook

For all the drama of a near-$400 billion merger rumour and a £17 billion one-day hit to its market value, AstraZeneca's underlying story in summer 2026 remains one of double-digit core earnings growth, a deep late-stage pipeline and a reaffirmed path toward $80 billion of revenue by 2030. The Bristol Myers episode showed how quickly sentiment can swing on unconfirmed reports, but on the evidence available, it was speculation that Reuters sources say never became a live deal. The more durable question for shareholders is whether AstraZeneca can keep delivering that growth organically, at the pace management has promised.